



Opinion

Shock therapy to treat the Novel Coronavirus Disease (COVID-19) by ddNTPs

Yeping Tan*

Wuhan Jinyitai Biological Co., Ltd., Biolake, Wuhan 430073, Hubei Province, China

Received: 18 April, 2020

Accepted: 19 May, 2020

Published: 20 May, 2020

*Corresponding author: Yeping Tan, Wuhan Jinyitai Biological Co., Ltd., Biolake, Wuhan 430073, Hubei Province, China,
E-mail: yeping747@163.com

<https://www.peertechz.com>



The Novel Coronavirus (SARS-CoV-2) has caused a massive global outbreak, presenting a significant public health emergency and international concern. Thousands of critically ill patients are dying daily. To date, there are no clinically approved antiviral drug available to cure the Novel Coronavirus infections. I highly recommend the clinical trial of 2',3'-dideoxyribonucleoside triphosphate (ddNTPs, except ddTTP) to be used for the Novel Coronavirus Disease (COVID-19) antiviral therapy. The Coronavirus replication in vivo could be inhibited immediately by very low concentration of ddUTP that is based on the Sager DNA sequencing

technique. Since the RNA of Coronavirus replication could be faster than host cells, ddUTP could give priority to virus rather than to host cells. Research and discussion of using concentration of ddUTP, time of ddUTP rejection, for the most severe cases are necessary to perform the clinic trial. Predictably, it should cause a toxic reaction to cells and organs in patients, even inducing patients' shack. Saving lives should be our utmost priority and it is necessary to process the valuable clinic trial immediately!

Discover a bigger Impact and Visibility of your article publication with Peertechz Publications

Highlights

- ❖ Signatory publisher of ORCID
- ❖ Signatory Publisher of DORA (San Francisco Declaration on Research Assessment)
- ❖ Articles archived in worlds' renowned service providers such as Portico, CNKI, AGRIS, TDNet, Base (Bielefeld University Library), CrossRef, Scilit, J-Gate etc.
- ❖ Journals indexed in ICMJE, SHERPA/ROMEO, Google Scholar etc.
- ❖ OAI-PMH (Open Archives Initiative Protocol for Metadata Harvesting)
- ❖ Dedicated Editorial Board for every journal
- ❖ Accurate and rapid peer-review process
- ❖ Increased citations of published articles through promotions
- ❖ Reduced timeline for article publication

Submit your articles and experience a new surge in publication services (<https://www.peertechz.com/submission>).

Peertechz journals wishes everlasting success in your every endeavours.

Copyright: © 2020 Tan Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.